BCL2A1: The underdog in the BCL2 family

Cell Death and Differentiation

Volumn 19, Issue 1, 2012, Pages 67-74

  Vogler, M ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

apoptosis; BCL2; BCL2A1; cancer

Indexed keywords

BCL2 RELATED PROTEIN A1; CYTOCHROME C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2;

APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL SURVIVAL; CHANNEL GATING; FETUS LIVER; GENE CONTROL; GENE EXPRESSION; GENE OVEREXPRESSION; GENE STRUCTURE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC SYSTEM; HUMAN; INFLAMMATION; LEUKOCYTE; MITOCHONDRIAL MEMBRANE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SOLID TUMOR; TUMOR GROWTH;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; GENE EXPRESSION REGULATION; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS; NF-KAPPA B; PROTEIN BINDING; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84856698334     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2011.158     Document Type: Review

References (103)

1. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190-195. (Pubitemid 27297457)
2. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F et al. Viral FLICEinhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997; 386: 517-521. (Pubitemid 27164081)
3. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
4. Labi V, Erlacher M, Kiessling S, Villunger A. BH3-only proteins in cell death initiation, malignant disease and anticancer therapy. Cell Death Differ 2006; 13: 1325-1338. (Pubitemid 44057468)
5. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899-905.
6. Lin EY, Kozak CA, Orlofsky A, Prystowsky MB. The bcl-2 family member, Bcl2a1, maps to mouse chromosome 9 and human chromosome 15. Mamm Genome 1997; 8: 293-294. (Pubitemid 28096630)
7. Choi SS, Park SH, Kim UJ, Shin HS. Bfl-1, a Bcl-2-related gene, is the human homolog of the murine A1, and maps to chromosome 15q24.3. Mamm Genome 1997; 8: 781-782. (Pubitemid 27439825)
8. Herman MD, Nyman T, Welin M, Lehtio L, Flodin S, Tresaugues L et al. Completing the family portrait of the anti-apoptotic Bcl-2 proteins: crystal structure of human Bfl-1 in complex with Bim. FEBS Lett 2008; 582: 3590-3594.
9. Brien G, Debaud AL, Robert X, Oliver L, Trescol-Biemont MC, Cauquil N et al. C-terminal residues regulate localization and function of the antiapoptotic protein Bfl-1. J Biol Chem 2009; 284: 30257-30263.
10. Ko JK, Lee MJ, Cho SH, Cho JA, Lee BY, Koh JS et al. Bfl-1S, a novel alternative splice variant of Bfl-1, localizes in the nucleus via its C-terminus and prevents cell death. Oncogene 2003; 22: 2457-2465. (Pubitemid 36560729)
11. Hatakeyama S, Hamasaki A, Negishi I, Loh DY, Sendo F, Nakayama K. Multiple gene duplication and expression of mouse bcl-2-related genes, A1. Int Immunol 1998; 10: 631-637. (Pubitemid 28221464)
12. Smits C, Czabotar PE, Hinds MG, Day CL. Structural plasticity underpins promiscuous binding of the prosurvival protein A1. Structure 2008; 16: 818-829. (Pubitemid 351615010)
13. Tao W, Kurschner C, Morgan JI. Modulation of cell death in yeast by the Bcl-2 family of proteins. J Biol Chem 1997; 272: 15547-15552. (Pubitemid 27255585)
14. Zhang H, Cowan-Jacob SW, Simonen M, Greenhalf W, Heim J, Meyhack B. Structural basis of BFL-1 for its interaction with BAX and its anti-apoptotic action in mammalian and yeast cells. J Biol Chem 2000; 275: 11092-11099. (Pubitemid 30212751)
15. Sedlak TW, Oltvai ZN, Yang E, Wang K, Boise LH, Thompson CB et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 1995; 92: 7834-7838.
16. Zhai D, Jin C, Huang Z, Satterthwait AC, Reed JC. Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1. J Biol Chem 2008; 283: 9580-9586.
17. Holmgreen SP, Huang DC, Adams JM, Cory S. Survival activity of Bcl-2 homologs Bcl-w and A1 only partially correlates with their ability to bind pro-apoptotic family members. Cell Death Differ 1999; 6: 525-532. (Pubitemid 29292108)
18. Simmons MJ, Fan G, Zong WX, Degenhardt K, White E, Gelinas C. Bfl-1/A1 functions, similar to Mcl-1, as a selective tBid and Bak antagonist. Oncogene 2008; 27: 1421-1428. (Pubitemid 351317460)
19. Werner AB, de Vries E, Tait SW, Bontjer I, Borst J. Bcl-2 family member Bfl-1/A1 sequesters truncated bid to inhibit is collaboration with pro-apoptotic Bak or Bax. J Biol Chem 2002; 277: 22781-22788. (Pubitemid 34967258)
20. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294-1305. (Pubitemid 41003019)
21. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351-365. (Pubitemid 43668734)
22. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403. (Pubitemid 40193310)
23. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-3428.
24. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324-1337. (Pubitemid 46328466)
25. Kathania M, Raje CI, Raje M, Dutta RK, Majumdar S. Bfl-1/A1 acts as a negative regulator of autophagy in mycobacteria infected macrophages. Int J Biochem Cell Biol 2011; 43: 573-585.
26. Kolluri SK, Zhu X, Zhou X, Lin B, Chen Y, Sun K et al. A short Nur77-derived peptide converts Bcl-2 from a protector to a killer. Cancer Cell 2008; 14: 285-298.
27. Orlofsky A, Berger MS, Prystowsky MB. Novel expression pattern of a new member of the MIP-1 family of cytokine-like genes. Cell Regul 1991; 2: 403-412.
28. Lin EY, Orlofsky A, Berger MS, Prystowsky MB. Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. J Immunol 1993; 151: 1979-1988. (Pubitemid 23235670)
29. Karsan A, Yee E, Harlan JM. Endothelial cell death induced by tumor necrosis factoralpha is inhibited by the Bcl-2 family member, A1. J Biol Chem 1996; 271: 27201-27204. (Pubitemid 26367264)
30. Karsan A, Yee E, Kaushansky K, Harlan JM. Cloning of human Bcl-2 homologue: inflammatory cytokines induce human A1 in cultured endothelial cells. Blood 1996; 87: 3089-3096. (Pubitemid 26115335)
31. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 1999; 13: 382-387. (Pubitemid 29108753)
32. Grumont RJ, Rourke IJ, Gerondakis S. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev 1999; 13: 400-411. (Pubitemid 29108756)
33. Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci USA 1999; 96: 9136-9141. (Pubitemid 29374720)
34. Craxton A, Chuang PI, Shu G, Harlan JM, Clark EA. The CD40-inducible Bcl-2 family member A1 protects B cells from antigen receptor-mediated apoptosis. Cell Immunol 2000; 200: 56-62. (Pubitemid 30170080)
35. Kater AP, Evers LM, Remmerswaal EB, Jaspers A, Oosterwijk MF, van Lier RA et al. CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the antiapoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. Br J Haematol 2004; 127: 404-415. (Pubitemid 39536592)
36. Morgan RK, Kingham PJ, Walsh MT, Curran DR, Durcan N, McLean WG et al. Eosinophil adhesion to cholinergic IMR-32 cells protects against induced neuronal apoptosis. J Immunol 2004; 173: 5963-5970. (Pubitemid 39487750)
37. He CH, Waxman AB, Lee CG, Link H, Rabach ME, Ma B et al. Bcl-2-related protein A1 is an endogenous and cytokine-stimulated mediator of cytoprotection in hyperoxic acute lung injury. J Clin Invest 2005; 115: 1039-1048. (Pubitemid 40489409)
38. Kim H, Kim YN, Kim CW. Oxidative stress attenuates Fas-mediated apoptosis in Jurkat T cell line through Bfl-1 induction. Oncogene 2005; 24: 1252-1261. (Pubitemid 40313926)
39. Liu TX, Zhang JW, Tao J, Zhang RB, Zhang QH, Zhao CJ et al. Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood 2000; 96: 1496-1504. (Pubitemid 30658482)
40. Jing Y, Wang L, Xia L, Chen GQ, Chen Z, Miller WH et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 2001; 97: 264-269. (Pubitemid 32061269)
41. Rasooly R, Schuster GU, Gregg JP, Xiao JH, Chandraratna RA, Stephensen CB. Retinoid x receptor agonists increase bcl2a1 expression and decrease apoptosis of naive T lymphocytes. J Immunol 2005; 175: 7916-7929. (Pubitemid 41798352)
42. Simpson LA, Burwell EA, Thompson KA, Shahnaz S, Chen AR, Loeb DM. The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy. Blood 2006; 107: 4695-4702. (Pubitemid 43882617)
43. Jenal M, Batliner J, Reddy VA, Haferlach T, Tobler A, Fey MF et al. The anti-apoptotic gene BCL2A1 is a novel transcriptional target of PU1. Leukemia 2010; 24: 1073-1076.
44. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002; 17: 51-62. (Pubitemid 34874618)
45. Herold MJ, Zeitz J, Pelzer C, Kraus C, Peters A, Wohlleben G et al. The stability and anti-apoptotic function of A1 are controlled by its C terminus. J Biol Chem 2006; 281: 13663-13671. (Pubitemid 43855282)
46. Kucharczak JF, Simmons MJ, Duckett CS, Gelinas C. Constitutive proteasome-mediated turnover of Bfl-1/A1 and its processing in response to TNF receptor activation in FL5.12 pro-B cells convert it into a prodeath factor. Cell Death Differ 2005; 12: 1225-1239. (Pubitemid 41195111)
47. Choi SS, Park IC, Yun JW, Sung YC, Hong SI, Shin HS. A novel Bcl-2 related gene, Bfl-1, is overexpressed in stomach cancer and preferentially expressed in bone marrow. Oncogene 1995; 11: 1693-1698.
48. Noble KE, Wickremasinghe RG, DeCornet C, Panayiotidis P, Yong KL. Monocytes stimulate expression of the Bcl-2 family member, A1, in endothelial cells and confer protection against apoptosis. J Immunol 1999; 162: 1376-1383. (Pubitemid 29307008)
49. Kenny JJ, Knobloch TJ, Augustus M, Carter KC, Rosen CA, Lang JC. GRS, a novel member of the Bcl-2 gene family, is highly expressed in multiple cancer cell lines and in normal leukocytes. Oncogene 1997; 14: 997-1001. (Pubitemid 27122432)
50. Xiang Z, Ahmed AA, Moller C, Nakayama K, Hatakeyama S, Nilsson G. Essential role of the prosurvival bcl-2 homologue A1 in mast cell survival after allergic activation. J Exp Med 2001; 194: 1561-1569. (Pubitemid 33126807)
51. Xiang Z, Moller C, Nilsson G. IgE-receptor activation induces survival and Bfl-1 expression in human mast cells but not basophils. Allergy 2006; 61: 1040-1046. (Pubitemid 44175210)
52. Karlberg M, Xiang Z, Nilsson G. Fc gamma RI-mediated activation of human mast cells promotes survival and induction of the pro-survival gene Bfl-1. J Clin Immunol 2008; 28: 250-255.
53. Su TT, Rawlings DJ. Transitional B lymphocyte subsets operate as distinct checkpoints in murine splenic B cell development. J Immunol 2002; 168: 2101-2110. (Pubitemid 34171808)
54. Tomayko MM, Cancro MP. Long-lived B cells are distinguished by elevated expression of A1. J Immunol 1998; 160: 107-111. (Pubitemid 28116721)
55. Tomayko MM, Punt JA, Bolcavage JM, Levy SL, Allman DM, Cancro MP. Expression of the Bcl-2 family member A1 is developmentally regulated in T cells. Int Immunol 1999; 11: 1753-1761. (Pubitemid 29533090)
56. Verschelde C, Walzer T, Galia P, Biemont MC, Quemeneur L, Revillard JP et al. A1/Bfl-1 expression is restricted to TCR engagement in T lymphocytes. Cell Death Differ 2003; 10: 1059-1067. (Pubitemid 37069483)
57. Tarte K, Jourdan M, Veyrune JL, Berberich I, Fiol G, Redal N et al. The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells. Br J Haematol 2004; 125: 373-382. (Pubitemid 38621770)
58. Jourdan M, Reme T, Goldschmidt H, Fiol G, Pantesco V, De Vos J et al. Gene expression of anti-and pro-apoptotic proteins in malignant and normal plasma cells. Br J Haematol 2009; 145: 45-58.
59. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10: 417-426. (Pubitemid 35007355)
60. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821-832.
61. Capuco AV, Li M, Long E, Ren S, Hruska KS, Schorr K et al. Concurrent pregnancy retards mammary involution: effects on apoptosis and proliferation of the mammary epithelium after forced weaning of mice. Biol Reprod 2002; 66: 1471-1476. (Pubitemid 34462292)
62. Thangaraju M, Sharan S, Sterneck E. Comparison of mammary gland involution between 129S1 and C57BL/6 inbred mouse strains: differential regulation of Bcl2a1, Trp53, Cebpb, and Cebpd expression. Oncogene 2004; 23: 2548-2553. (Pubitemid 38520751)
63. Chuang PI, Morefield S, Liu CY, Chen S, Harlan JM, Willerford DM. Perturbation of B-cell development in mice overexpressing the Bcl-2 homolog A1. Blood 2002; 99: 3350-3359. (Pubitemid 34525316)
64. Gonzalez J, Orlofsky A, Prystowsky MB. A1 is a growth-permissive antiapoptotic factor mediating postactivation survival in T cells. Blood 2003; 101: 2679-2685. (Pubitemid 36857630)
65. Verschelde C, Michonneau D, Trescol-Biemont MC, Berberich I, Schimpl A, Bonnefoy-Berard N. Overexpression of the antiapoptotic protein A1 promotes the survival of double positive thymocytes awaiting positive selection. Cell Death Differ 2006; 13: 1213-1221. (Pubitemid 43905601)
66. McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 1991; 349: 254-256. (Pubitemid 21912060)
67. Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, Negishi I et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 1995; 267: 1506-1510.
68. Rinkenberger JL, Horning S, Klocke B, Roth K, Korsmeyer SJ. Mcl-1 deficiency results in peri-implantation embryonic lethality. Genes Dev 2000; 14: 23-27. (Pubitemid 30051575)
69. Hamasaki A, Sendo F, Nakayama K, Ishida N, Negishi I, Hatakeyama S. Accelerated neutrophil apoptosis in mice lacking A1-a, a subtype of the bcl-2-related A1 gene. J Exp Med 1998; 188: 1985-1992. (Pubitemid 28562516)
70. Oberdoerffer P, Kanellopoulou C, Heissmeyer V, Paeper C, Borowski C, Aifantis I et al. Efficiency of RNA interference in the mouse hematopoietic system varies between cell types and developmental stages. Mol Cell Biol 2005; 25: 3896-3905. (Pubitemid 40617641)
71. Nagy B, Lundan T, Larramendy ML, Aalto Y, Zhu Y, Niini T et al. Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma. Br J Haematol 2003; 120: 434-441. (Pubitemid 36241499)
72. Morales AA, Olsson A, Celsing F, Osterborg A, Jondal M, Osorio LM. High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia. Int J Cancer 2005; 113: 730-737. (Pubitemid 40101253)
73. Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, Cattoretti G et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005; 106: 1392-1399. (Pubitemid 41129606)
74. Mahadevan D, Spier C, Della Croce K, Miller S, George B, Riley C et al. Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. Mol Cancer Ther 2005; 4: 1867-1879. (Pubitemid 43056970)
75. Piva R, Pellegrino E, Mattioli M, Agnelli L, Lombardi L, Boccalatte F et al. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest 2006; 116: 3171-3182. (Pubitemid 44878631)
76. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105: 1851-1861. (Pubitemid 40731764)
77. Park IC, Lee SH, Whang DY, Hong WS, Choi SS, Shin HS et al. Expression of a novel Bcl-2 related gene, Bfl-1, in various human cancers and cancer cell lines. Anticancer Res 1997; 17: 4619-4622. (Pubitemid 28081755)
78. Beverly LJ, Varmus HE. MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family. Oncogene 2009; 28: 1274-1279.
79. Yoon HS, Hong SH, Kang HJ, Ko BK, Ahn SH, Huh JR. Bfl-1 gene expression in breast cancer: its relationship with other prognostic factors. J Korean Med Sci 2003; 18: 225-230. (Pubitemid 38011289)
80. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 2008; 1: 13.
81. Lee CF, Ling ZQ, Zhao T, Fang SH, Chang WC, Lee SC et al. Genomic-wide analysis of lymphatic metastasis-associated genes in human hepatocellular carcinoma. World J Gastroenterol 2009; 15: 356-365.
82. Kathpalia VP, Mussak EN, Chow SS, Lam PH, Skelley N, Time M et al. Genome-wide transcriptional profiling in human squamous cell carcinoma of the skin identifies unique tumor-associated signatures. J Dermatol 2006; 33: 309-318. (Pubitemid 43943363)
83. Saleh A, Zain RB, Hussaini H, Ng F, Tanavde V, Hamid S et al. Transcriptional profiling of oral squamous cell carcinoma using formalin-fixed paraffin-embedded samples. Oral Oncol 2010; 46: 379-386.
84. D'Sa-Eipper C, Subramanian T, Chinnadurai G. bfl-1, a bcl-2 homologue, suppresses p53-induced apoptosis and exhibits potent cooperative transforming activity. Cancer Res 1996; 56: 3879-3882. (Pubitemid 26284731)
85. Mandal M, Borowski C, Palomero T, Ferrando AA, Oberdoerffer P, Meng F et al. The BCL2A1 gene as a pre-T cell receptor-induced regulator of thymocyte survival. J Exp Med 2005; 201: 603-614. (Pubitemid 40289550)
86. Fan G, Simmons MJ, Ge S, Dutta-Simmons J, Kucharczak J, Ron Y et al. Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma. Blood 2010; 115: 3559-3569.
87. Yajima T, Ochiai H, Uchiyama T, Takano N, Shibahara T, Azuma T. Resistance to cytotoxic chemotherapy-induced apoptosis in side population cells of human oral squamous cell carcinoma cell line Ho-1-N-1. Int J Oncol 2009; 35: 273-280.
88. Wang CY, Guttridge DC, Mayo MW, Baldwin Jr AS. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999; 19: 5923-5929. (Pubitemid 29399297)
89. Shim YH, Byun EK, Lee MJ, Huh J, Kim CW. Anti-apoptotic role of Bfl-1 in staurosporinetreated B-lymphoblastic cells. Int J Hematol 2000; 72: 484-490.
90. Cheng Q, Lee HH, Li Y, Parks TP, Cheng G. Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappaB inhibition. Oncogene 2000; 19: 4936-4940.
91. Brien G, Trescol-Biemont MC, Bonnefoy-Berard N. Downregulation of Bfl-1 protein expression sensitizes malignant B cells to apoptosis. Oncogene 2007; 26: 5828-5832. (Pubitemid 47312815)
92. Olsson A, Norberg M, Okvist A, Derkow K, Choudhury A, Tobin G et al. Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia. Br J Cancer 2007; 97: 769-777. (Pubitemid 47396296)
93. Campone M, Campion L, Roche H, Gouraud W, Charbonnel C, Magrangeas F et al. Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen. Breast Cancer Res Treat 2008; 109: 491-501. (Pubitemid 351692060)
94. Kim JK, Kim KD, Lee E, Lim JS, Cho HJ, Yoon HK et al. Up-regulation of Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant human bladder cancer cell line. Cancer Lett 2004; 212: 61-70. (Pubitemid 38887721)
95. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ et al. Concurrent upregulation of BCL-XL and BCL2A1 induces B1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009; 113: 4403-4413.
96. Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010; 115: 3304-3313.
97. Vogler M, Dinsdale D, Dyer MJ, Cohen GM. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 2009; 16: 360-367.
98. Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJ et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 2009; 16: 1030-1039.
99. Zhai D, Jin C, Shiau CW, Kitada S, Satterthwait AC, Reed JC. Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther 2008; 7: 1639-1646.
100. Cashman JR, MacDonald M, Ghirmai S, Okolotowicz KJ, Sergienko E, Brown B et al. Inhibition of Bfl-1 with N-aryl maleimides. Bioorg Med Chem Lett 2010; 20: 6560-6564.
101. Wei J, Kitada S, Rega MF, Emdadi A, Yuan H, Cellitti J et al. Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther 2009; 8: 904-913.
102. Brien G, Debaud AL, Bickle M, Trescol-Biemont MC, Moncorge O, Colas P et al. Characterization of peptide aptamers targeting Bfl-1 anti-apoptotic protein. Biochemistry 2011; 50: 5120-5129.
103. Tromp JM, Tonino SH, Elias JA, Jaspers A, Luijks DM, Kater AP et al. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chainmutated versus unmutated CLL cells upon CD40/TLR9 triggering. Oncogene 2010; 29: 5071-5082.